Skip to main content
search

Two New Stabs at Vaccinating People Against Pathologic Tau

Bells and Whistles. ACI-35.030 includes a phospho-tau peptide anchored to a liposomal bilayer, along with two adjuvants and a non-target T cell epitope to rally B cells to churn out antibodies against phospho-tau. [Courtesy of Johannes Streffer, AC Immune]

The work of our faculty, researchers, and collaborators was highlighted in a recent Alzforum article on anti-tau vaccines.

  • AC Immune updates Phase 1b/2 comparison of two anti-#tau vaccines.
  • A liposomal vaccine prompted #antibody response against phospho-tau.
  • Preclinical data bode well for another tau vaccine; first trial slated for next year.

Read more >

Related posts:

  1. From data to decision-making: the role of machine learning and digital twins in Alzheimer’s Disease For patients experiencing cognitive decline due to Alzheimer’s Disease (AD), choosing the most appropriate treatment course at the right time is of great importance. A key element to these decisions is the careful consideration of the available scientific evidence, particularly from randomized clinical trials (RCTs) such as the recent lecanemab...
  2. FDA Approves Donanemab Today, the US Food and Drug Administration granted full clinical approval to Eli Lilly to market donanemab, brand name KISUNLA, for the treatment of early Alzheimer’s disease, including Mild Cognitive Impairment (MCI) or mild dementia. Donanemab is a monoclonal antibody against the beta-amyloid protein that accumulates in the brain of...
  3. Keeping sleep in mind: poor sleep and dementia risk A recent article in the New York Times, How Poor Sleep Affects Your Risk of Dementia, summarizes some recent findings showing both excessively short and long sleep, as well as sleep disorders such as sleep apnea, insomnia, and rapid-eye movement (REM) behavior disorder, may be linked with risk for Alzheimer’s...
Close Menu